Pharmacovigilance

PI: Trevor Cohen, MBChB, PhD

Funding Agency: National Library of Medicine (1R01LM011563-01)

09/01/2013-08/31/2016

Summary: The need to monitor unintended effects of approved drugs has been highlighted by several recent high-profile events in which fatal side effects of drugs were detected after their release to market. Notoriously, the Cox-2 inhibitor Rofecoxib (Vioxx) was withdrawn from market on account of evidence suggesting that treatment with the drug increased the rate of coronary artery disease, and recently new evidence has emerged suggesting the commonly used antibiotic Azithromycin (Zithromax) may cause fatal arrhythmia. In an effort to mitigate the morbidity and mortality resulting from such undetected side effects, regulatory bodies such as the Food and Drug Administration (FDA) have instituted spontaneous reporting systems to systematize post-marketing surveillance. However there is evidence that under-reporting of adverse drug events (ADEs) is widespread. Automated monitoring of events documented in the Electronic Health Record (EHR) as free text or structured data has been proposed as a path toward earlier identification of meaningfully correlated drug-event pairs. As these pairs must ultimately be reviewed by domain experts to assess their implications, there is a pressing need to develop methods to selectively identify plausible drug-event pairs within the large pool of correlations to be found in clinical data. In the proposed research, we will develop and evaluate models of biological plausibility, based on knowledge extracted from the biomedical literature and using methods of hyper-dimensional computing for efficient search and inference across multiple concepts and relations simultaneously. These methods will be used to selectively identify plausible drug-event pairs extracted from unstructured data using natural language processing. If successful, the proposed research will provide the means to identify automatically plausible drug-event pairs for regulatory purposes, constraining the consequences of previously undetected side effects. In addition, the methods will provide a generalizable approach that can be used to apply knowledge derived from the biomedical literature to interpret clinical data.